Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

Background: Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages remain unclear. The latest prognostic outcomes in clinical Stage (cStage) II/III ESCC with NAC were herein elucidated. Patients and Methods: NAC prior...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology 2017-01, Vol.92 (4), p.221-228
Hauptverfasser:	Yamashita, Keishi, Hosoda, Kei, Moriya, Hiromitsu, Katada, Chikatoshi, Sugawara, Mitsuhiro, Mieno, Hiroaki, Komori, Shoko, Katada, Natsuya, Watanabe, Masahiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant chemotherapy Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - surgery Care and treatment Cisplatin - administration & dosage Clinical Study Development and progression Docetaxel Drug therapy Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Esophageal Squamous Cell Carcinoma Esophagectomy Female Fluorouracil - administration & dosage Humans Lymphatic Metastasis Male Middle Aged Neoadjuvant Therapy Neoplasm Recurrence, Local Neoplasm Staging Patient outcomes Postoperative Period Preoperative Care Prevention Prognosis Prospective Studies Squamous cell carcinoma Taxoids - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!